Crinetics Pharmaceuticals (CRNX) Competitors $30.38 -0.04 (-0.12%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. QGEN, VTRS, ASND, VRNA, BBIO, BPMC, ROIV, LEGN, ELAN, and RGCShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Its Competitors QIAGEN Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Legend Biotech Elanco Animal Health Regencell Bioscience Crinetics Pharmaceuticals (NASDAQ:CRNX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Is CRNX or QGEN more profitable? Qiagen has a net margin of 4.68% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Qiagen's return on equity of 14.61% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% Qiagen 4.68%14.61%8.80% Does the media prefer CRNX or QGEN? In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Crinetics Pharmaceuticals and 6 mentions for Qiagen. Crinetics Pharmaceuticals' average media sentiment score of 1.48 beat Qiagen's score of 1.21 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qiagen 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CRNX or QGEN? Crinetics Pharmaceuticals currently has a consensus target price of $69.50, suggesting a potential upside of 128.81%. Qiagen has a consensus target price of $49.40, suggesting a potential downside of 4.22%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Which has more volatility & risk, CRNX or QGEN? Crinetics Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Which has better earnings and valuation, CRNX or QGEN? Qiagen has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M2,734.63-$298.41M-$3.82-7.95Qiagen$1.98B5.80$83.59M$0.40128.94 Do institutionals and insiders hold more shares of CRNX or QGEN? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryQiagen beats Crinetics Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84B$2.76B$5.70B$9.52BDividend YieldN/A1.78%4.60%3.99%P/E Ratio-7.949.0628.0020.01Price / Sales2,734.63738.63457.41102.39Price / CashN/A166.2336.5558.97Price / Book2.135.158.595.87Net Income-$298.41M$30.99M$3.24B$258.50M7 Day Performance-2.36%7.15%3.71%1.95%1 Month Performance-0.12%15.55%10.26%12.31%1 Year Performance-43.05%-1.12%34.07%19.02% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.6781 of 5 stars$30.38-0.1%$69.50+128.8%-43.1%$2.84B$1.04M-7.94210Positive NewsQGENQIAGEN3.7063 of 5 stars$48.06-0.6%$49.40+2.8%+25.6%$10.75B$1.98B20.925,765Positive NewsAnalyst RevisionVTRSViatris2.3592 of 5 stars$8.90+0.2%$10.40+16.9%-20.1%$10.42B$14.74B3.5832,000ASNDAscendis Pharma A/S3.4985 of 5 stars$168.02-1.1%$223.07+32.8%+25.6%$10.39B$393.54M0.001,017Analyst RevisionVRNAVerona Pharma PLC American Depositary Share2.6872 of 5 stars$104.90flat$109.00+3.9%+398.3%$8.93B$42.28M0.0030Positive NewsBBIOBridgeBio Pharma4.6151 of 5 stars$45.90-1.3%$61.50+34.0%+73.2%$8.83B$221.90M0.00400BPMCBlueprint Medicines0.972 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsROIVRoivant Sciences2.6491 of 5 stars$11.48+0.3%$16.50+43.7%+5.9%$7.78B$29.05M0.00860News CoveragePositive NewsInsider TradeLEGNLegend Biotech3.6854 of 5 stars$42.23+1.5%$73.33+73.7%-25.9%$7.64B$627.24M0.002,609Positive NewsELANElanco Animal Health3.3886 of 5 stars$14.67-0.8%$16.00+9.1%+12.7%$7.34B$4.44B15.729,000Analyst ForecastRGCRegencell Bioscience0.3073 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Gap Down Related Companies and Tools Related Companies QIAGEN Competitors Viatris Competitors Ascendis Pharma A/S Competitors Verona Pharma PLC American Depositary Share Competitors BridgeBio Pharma Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Legend Biotech Competitors Elanco Animal Health Competitors Regencell Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRNX Stock Alerts